Bevacizumab effective against macular oedema

Intravitreal ranibizumab appears to be an effective treatment for macular oedema secondary to retinal vein occlusion, according to the results of a prospective trial. The study involved 40 consecutive eyes of 41 patients with branch or central retinal vein occlusion. All received three initial intravitreal injections of 0.5mg ranibizumab at monthly intervals, with further retreatment based on visual acuity changes and OCT findings. In patients with branch retinal vein occlusion, the mean logMAR BCVA improved significantly from the baseline value 0.76 to 0.19 at 12 months’ follow-up (± 0.18 (p = 0.000). There was also an improvement in mean logMAR BCVA at 12 months among eyes with central retinal vein occlusion, from 0.84 to 0.39, although it did not reach statistical significance.
(Kim et al, Ophthalmologica 2012; DOI:10.1159/000334906).
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.